L
Louis McMahon
Researcher at Novartis
Publications - 8
Citations - 1291
Louis McMahon is an academic researcher from Novartis. The author has contributed to research in topics: Everolimus & Transplantation. The author has an hindex of 7, co-authored 8 publications receiving 1262 citations.
Papers
More filters
Journal ArticleDOI
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
Pradip K. Majumder,Phillip G. Febbo,Phillip G. Febbo,Rachel Bikoff,Rachel Bikoff,Raanan Berger,Raanan Berger,Qi Xue,Qi Xue,Louis McMahon,Judith Manola,James Brugarolas,James Brugarolas,Timothy J. McDonnell,Todd R. Golub,Todd R. Golub,Todd R. Golub,Massimo Loda,Massimo Loda,Heidi Lane,William R. Sellers,William R. Sellers,William R. Sellers +22 more
TL;DR: It is reported that mTOR inhibition induced apoptosis of epithelial cells and the complete reversal of a neoplastic phenotype in the prostate of mice expressing human AKT1 in the ventral prostate, and that clinical resistance to mTOR inhibitors may emerge through BCL2 expression and/or upregulation of HIF-1α activity.
Journal ArticleDOI
Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.
TL;DR: Everolimus is a macrolide immunosuppressant intended for acute rejection prophylaxis after kidney transplantation.
Journal ArticleDOI
High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood.
TL;DR: A marked improvement in sample throughput efficiency was realized with this LLE method when compared to existing solid phase extraction (SPE) methods which deal with both RAD001 and CsA.
Journal ArticleDOI
Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation.
John M. Kovarik,Bruce Kaplan,Helio Tedesco Silva,Barry D. Kahan,Jacques Dantal,Louis McMahon,Stephane Berthier,Chyi Hung Hsu,Christiane Rordorf +8 more
TL;DR: Everolimus exposure was relatively stable over the first 6’months post transplant, with no major departure from dose‐proportionality over the therapeutic dose range, and weight‐adjusted dosing (mg/kg) does not appear warranted.
Journal ArticleDOI
High‐throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi‐automated 96‐well solid‐phase extraction system
TL;DR: The sensitivity, small sample volume needed and high sample throughput of this liquid chromatography/mass spectrometry procedure make it an attractive option for pharmacokinetic studies in pediatric patients.